News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
754,193 Results
Type
Article (57518)
Company Profile (661)
Press Release (696014)
Section
Business (218318)
Career Advice (2810)
Deals (37848)
Drug Delivery (110)
Drug Development (86293)
Employer Resources (179)
FDA (17593)
Job Trends (16212)
News (372066)
Policy (37236)
Tag
Academia (2902)
Alliances (53617)
Alzheimer's disease (1317)
Approvals (17509)
Artificial intelligence (150)
Bankruptcy (379)
Best Places to Work (12316)
Biotechnology (458)
Breast cancer (128)
Cancer (1152)
Cardiovascular disease (108)
Career advice (2361)
Cell therapy (256)
Clinical research (68285)
Collaboration (408)
Compensation (204)
COVID-19 (2789)
C-suite (102)
Data (1142)
Diabetes (166)
Diagnostics (6575)
Earnings (88948)
Employer resources (157)
Events (117634)
Executive appointments (322)
FDA (18147)
Funding (367)
Gene therapy (195)
GLP-1 (664)
Government (4868)
Healthcare (20214)
Infectious disease (2881)
Inflammatory bowel disease (119)
Interviews (496)
IPO (17112)
Job creations (4317)
Job search strategy (1989)
Layoffs (467)
Legal (9240)
Lung cancer (185)
Manufacturing (197)
Medical device (14138)
Medtech (14143)
Mergers & acquisitions (20789)
Metabolic disorders (452)
Neuroscience (1617)
NextGen Class of 2024 (7338)
Non-profit (4945)
Northern California (1503)
Obesity (257)
Opinion (229)
Patents (110)
People (60250)
Pharmaceutical (130)
Phase I (21108)
Phase II (29845)
Phase III (22471)
Pipeline (461)
Postmarket research (3022)
Preclinical (9145)
Radiopharmaceuticals (254)
Rare diseases (238)
Real estate (6618)
Regulatory (24529)
Research institute (2586)
Resumes & cover letters (462)
Southern California (1335)
Startups (3958)
United States (14250)
Vaccines (640)
Weight loss (206)
Date
Today (137)
Last 7 days (864)
Last 30 days (3942)
Last 365 days (37827)
2024 (34653)
2023 (42036)
2022 (53393)
2021 (58165)
2020 (57046)
2019 (50265)
2018 (38243)
2017 (35326)
2016 (35344)
2015 (41223)
2014 (35184)
2013 (30569)
2012 (32685)
2011 (33291)
2010 (31424)
Location
Africa (971)
Arizona (212)
Asia (43786)
Australia (7327)
California (3494)
Canada (1298)
China (258)
Colorado (152)
Connecticut (167)
Europe (96445)
Florida (465)
Georgia (126)
Illinois (378)
Indiana (212)
Kansas (101)
Maryland (624)
Massachusetts (2798)
Michigan (165)
Minnesota (287)
New Jersey (987)
New York (984)
North Carolina (792)
Northern California (1503)
Ohio (146)
Pennsylvania (860)
South America (1359)
Southern California (1335)
Texas (495)
Washington State (388)
754,193 Results for "idorsia pharmaceuticals us inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Idorsia’s once-daily TRYVIO™ (aprocitentan) is now available in the U.S., advancing treatment options for millions of patients with difficult-to-control hypertension
November 18, 2024
·
13 min read
FDA
US FDA approves Idorsia’s once-daily TRYVIO (aprocitentan) - the first and only endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled in combination with other antihypertensives
Idorsia Pharmaceuticals U.S. Inc. announced today that the US Food and Drug Administration (FDA) has approved TRYVIO™ (aprocitentan) for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult patients who are not adequately controlled on other drugs.
March 20, 2024
·
19 min read
Press Releases
Idorsia announces financial results for the first nine months of 2024
October 29, 2024
·
22 min read
Pharm Country
Tausif (‘Tosh’) Butt to Join Idorsia Pharmaceuticals U.S. as President and General Manager
Idorsia Pharmaceuticals U.S. Inc. announced that Tausif Butt will join the organization as the new President and General Manager on September 5, 2023.
August 31, 2023
·
5 min read
Press Releases
Idorsia is advancing the treatment of hypertension with new data at the 2024 American Heart Association (AHA) Scientific Sessions
November 12, 2024
·
5 min read
Business
Idorsia and Viatris enter into a significant global research and development collaboration
Idorsia Ltd announced that it has entered into agreements for a significant global research and development collaboration with Viatris Inc.
February 28, 2024
·
9 min read
Business
Viatris and Idorsia Enter Into Significant Global Research and Development Collaboration
Viatris Inc. and Idorsia Ltd announced they have entered into agreements for a significant global research and development collaboration under which Viatris will receive exclusive global development and commercialization rights to two Phase 3 assets as well as the potential to add additional innovative assets in the future.
February 28, 2024
·
16 min read
Business
Viatris, Idorsia Ink $350M R&D Pact for Two Phase III Assets
Under the research and development agreement announced Wednesday, Viatris is securing global rights to Idorsia’s late-stage heart and lupus candidates.
February 28, 2024
·
2 min read
·
Tyler Patchen
FDA
Idorsia Wins FDA Approval in Hypertension Months After J&J Returned Rights to Drug
Months after Johnson & Johnson turned its back on the hypertension treatment Tryvio, Idorsia has secured the FDA’s nod for the endothelin receptor blocker.
March 21, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Idorsia announces financial results for the first half 2024
July 25, 2024
·
26 min read
1 of 75,420
Next
